BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, February 15, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinib in combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients. BGBC008 Topline Data The open-label, multi-